MedPath

Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Clinical Trials
Related News

FDA Grants IND Clearance for Immunoglobulin Eye Drops to Treat Dry Eye Disease

• The FDA has granted Investigational New Drug clearance for immunoglobulin eye drops (SLG-100/GRF312), developed by Selagine and Grifols, to treat dry eye disease in upcoming Phase II clinical trials. • The novel treatment offers broad-spectrum anti-inflammatory and immunomodulatory properties, potentially providing mechanistic superiority over current narrow-spectrum therapies that primarily target T-cell inflammation. • A first-in-human pilot trial demonstrated significant reduction in dry eye symptoms with no difference in tolerability or adverse events compared to vehicle, showing promise for the over 100 million people affected globally.

Eyenovia and Betaliq Plan Reverse Merger to Create Innovative Ophthalmic Technology Company

• Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity. • The merger would combine Betaliq's EyeSol® water-free drug delivery technology for glaucoma with Eyenovia's Optejet® device platform, potentially creating a revolutionary approach to topical eye medication administration. • If completed, the combined company would continue marketing Eyenovia's FDA-approved products while developing new treatment options for glaucoma and other ocular diseases through established partnerships.

Dupilumab Shows Strong Efficacy in Chronic Spontaneous Urticaria Across All BMI Ranges

• Phase 3 LIBERTY-CSU CUPID trials demonstrate dupilumab's effectiveness in reducing itch and urticaria activity in patients unresponsive to H1-antihistamines. • Clinical benefits of dupilumab were consistent across all BMI ranges, including patients in obese categories, providing important efficacy data for diverse patient populations. • FDA review of dupilumab for chronic spontaneous urticaria is underway with a target action date of April 18, 2025, potentially offering a new treatment option for resistant cases.

Thetis Reports Positive Phase 1a Data for Novel IBD Drug TP-317, Demonstrating BLT1 Target Engagement

• Phase 1a trial of TP-317, a first-in-class BLT1 receptor-targeting drug for IBD, demonstrates favorable safety profile and successful target engagement in healthy volunteers. • Single ascending doses up to 80mg showed dose-proportional increases in Resolvin E1 exposure, with no treatment-related adverse events reported. • Preclinical data reveals TP-317's multi-modal mechanism providing anti-inflammatory effects, gut barrier protection, and pain relief potential for IBD patients.

OMNI® Surgical System Shows Long-Term Efficacy in Comprehensive 22-Study Meta-Analysis for Glaucoma Treatment

• Meta-analysis of 22 studies demonstrates significant long-term intraocular pressure reduction and decreased medication dependence using the OMNI® Surgical System for glaucoma treatment. • Real-world data from the IRIS® Registry confirms sustained effectiveness of standalone canaloplasty and trabeculotomy procedures over 36 months in primary open-angle glaucoma patients. • New analysis from the ROMEO Study reveals OMNI® achieves comparable pressure and medication reductions across mild, moderate, and advanced glaucoma cases.

IASO Bio's CAR-T Therapy, Equecabtagene Autoleucel, Advances in Hong Kong and Singapore for Multiple Myeloma

• IASO Bio's Equecabtagene Autoleucel (FUCASO) NDA has been accepted by the Hong Kong Department of Health for relapsed/refractory multiple myeloma. • The CAR-T therapy, already approved in China, is the first fully human CAR-T product and has shown remarkable efficacy and safety. • Singapore Health Sciences Authority (HSA) has also accepted the NDA for Equecabtagene Autoleucel, marking a key step in IASO Bio's global expansion. • IASO Bio plans to implement a 'Manufactured in China, supplied overseas' model upon approval, expanding access to CAR-T therapies.

Madrigal's Rezdiffra Shows Promise in MASH Cirrhosis with Two-Year Data

• Madrigal Pharmaceuticals reports Rezdiffra (resmetirom) demonstrates potential benefits in patients with compensated MASH cirrhosis (F4c). • Two-year data from the MAESTRO-NAFLD-1 trial shows a mean 6.7 kPa reduction in liver stiffness, the largest reported in this patient group. • 51% of patients achieved a ≥25% reduction in liver stiffness, associated with reduced progression to end-stage liver disease. • Rezdiffra's safety profile remains consistent, supporting its potential as a treatment for F2-F4c MASH pending further trial outcomes.

BlueRock Therapeutics' Bemdaneprocel Advances to Phase 3 for Parkinson's Disease

• BlueRock Therapeutics is initiating a Phase 3 trial, exPDite-2, for bemdaneprocel, a cell therapy for Parkinson's disease, expected to begin in the first half of 2025. • The exPDite-2 trial will enroll 102 patients with moderate Parkinson's, assessing the change in 'on' time without dyskinesia over 78 weeks compared to a sham surgery. • Bemdaneprocel aims to replace dopamine-producing neurons lost in Parkinson's, with Phase 1 data showing tolerability and encouraging trends in motor function. • The FDA granted bemdaneprocel Regenerative Medicine Advanced Therapy (RMAT) designation, potentially accelerating its development and review process.

FDA Accepts Aldeyra's Reproxalap NDA for Dry Eye Disease with AbbVie Collaboration

• The FDA has accepted Aldeyra Therapeutics' New Drug Application (NDA) for reproxalap, a topical ocular therapy for dry eye disease, with a PDUFA date of April 2, 2025. • Reproxalap, a first-in-class RASP modulator, has demonstrated significant clinical efficacy and safety in reducing the signs and symptoms of dry eye disease in multiple late-stage trials. • Aldeyra has expanded its collaboration with AbbVie to accelerate pre-commercial activities, with AbbVie covering 60% of the costs and a potential $100 million upfront payment upon exercising its option. • The partnership includes up to $300 million in milestone payments and a profit-sharing model for U.S. commercialization, positioning reproxalap as a potential game-changer in dry eye disease treatment.

Novel Drug Regimens Show Promise in Reducing Graft-versus-Host Disease After Stem Cell Transplants

• A novel drug regimen (SIR/CSP/PTCy) significantly reduced moderate to severe chronic graft-versus-host disease (cGVHD) to 1% compared to 28% with the SIR/CSP/MMF regimen. • The SIR/CSP/PTCy regimen also improved one-year cGVHD-free relapse-free survival, showing 76% compared to 55% in the control group. • A Phase I trial of itacitinib showed promising results in preventing severe graft-versus-host disease (GvHD) in half-matched stem cell transplants, with no grade 3 or 4 GvHD observed. • Itacitinib, a JAK inhibitor, is being investigated for its potential to prevent GvHD when administered before stem cell transplantation, representing a new approach to managing this complication.

Soligenix Initiates Phase 2 Trial of Dusquetide (SGX945) for Behçet's Disease

• Soligenix has commenced patient enrollment in a Phase 2 clinical trial evaluating SGX945 (dusquetide) for the treatment of Behçet's Disease. • The open-label study will enroll approximately 25 patients with mild to moderate Behçet's Disease, assessing lesion clearance and quality of life. • Dusquetide, an innate defense regulator, aims to modulate the body's inflammatory response and promote tissue healing in Behçet's Disease ulcers. • Topline results from the Phase 2 trial are expected in the first half of 2025, offering hope for an underserved patient population.

Palisade Bio's PALI-2108 Shows Promise in Ulcerative Colitis Preclinical Studies

• PALI-2108, a colon-specific PDE4 inhibitor prodrug, effectively reduced colitis symptoms in a DSS mouse model, suggesting potential for ulcerative colitis (UC) treatment. • The preclinical data indicates that PALI-2108 does not exhibit CNS toxicity, a common concern with systemically acting PDE4 inhibitors, enhancing its safety profile. • Palisade Bio is advancing PALI-2108 through a Phase 1a/b study, with topline data expected in the first half of 2025, marking progress in clinical development. • Pharmacokinetic modeling suggests favorable absorption and bioavailability of PALI-2108, supporting its potential for clinical use with twice-daily induction and once-daily maintenance dosing.
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy